VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MGTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MGTXMeiraGTx Holdings plc
$8.32$771M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksMGTXBalance Sheet

MeiraGTx Holdings plc (MGTX) Balance Sheet

10Y historyFree accessUpdated daily

Total debt climbed from $80.5M in 2025Q2 to $133.9M in 2026Q3, and the debt-to-equity ratio of 0.62 appears to reflect equity rebuilt through a single recognition event rather than any reduction in absolute leverage.

Income StatementBalance SheetCash FlowRatios

MGTX Balance Sheet

Annual statement

MGTX Balance Sheet

MeiraGTx Holdings plc (MGTX) balance sheet — 10-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16
Total Current Assets242.35M91.76M123.52M159.62M154.34M183.24M272.58M268.98M74.65M11.48M19.09M
Cash & Short-Term Investments184.65M65.93M103.66M129.57M115.52M137.7M209.52M227.23M68.08M8.55M17.48M
Cash Only184.65M65.93M103.66M129.57M115.52M137.7M209.52M227.23M68.08M8.55M17.48M
Short-Term Investments00000000000
Accounts Receivable29.56M18.29M10.63M23.41M29.02M35.02M55.41M37.11M000
Days Sales Outstanding24.9982116.57609.72665.41339.021.3K1.02K---
Inventory00385K00000000
Days Inventory Outstanding--5.91--------
Other Current Assets24.31M1.53M2.02M1.02M1.67M2.42M564.44K170.59K4.63M965.23K400.96K
Total Non-Current Assets169.35M152.67M146.23M167.12M163.9M136.92M91.12M54.91M22.24M14.38M3.46M
Property, Plant & Equipment129.86M141.93M135.65M156.24M154.09M126.29M87.12M52.86M22.01M14.26M3.02M
Fixed Asset Turnover2.96x0.57x0.25x0.09x0.10x0.30x0.18x0.25x---
Goodwill00000000000
Intangible Assets17K578K821K1.12M2.08M2.57M2.97M777.65K000
Long-Term Investments89.33M6.75M6.75M6.77M6.33M6.66M0123.38K123.38K123.38K444.84K
Other Non-Current Assets3.47M3.41M3.01M3M1.4M1.4M1.03M1.15M105.08K00
Total Assets411.69M244.43M269.75M326.74M318.24M320.16M363.7M323.89M96.89M25.85M22.55M
Asset Turnover1.24x0.33x0.12x0.04x0.05x0.12x0.04x0.04x---
Asset Growth %216.62%-9.39%-17.44%2.67%-0.6%-11.97%12.29%234.27%274.77%14.65%-
Total Current Liabilities52.4M122.56M60.78M67.08M82.07M68.13M54.15M49.2M15.5M21.4M6.04M
Accounts Payable10.91M10.07M23.59M16.04M16.62M15.35M7.13M3.76M3.04M7.06M1.47M
Days Payables Outstanding262.86758.64361.85-----5413.79K2.21K
Short-Term Debt024.65M00002.58M1.67M01.44M0
Deferred Revenue (Current)14.46M1.78M4.83M2.93M15.12M21.82M23.54M25.68M11.99M10.19M-6.01K
Other Current Liabilities16.28M63.09M12.1M41.28M16.23M6.03M17.09M11.23M-5.82M2.68M1.96M
Current Ratio4.62x0.75x2.03x2.38x1.88x2.69x5.03x5.47x4.82x0.54x3.16x
Quick Ratio4.62x0.75x2.03x2.38x1.88x2.69x5.03x5.47x4.82x0.54x3.16x
Cash Conversion Cycle-237.87--239.38--------
Total Non-Current Liabilities144.07M127.67M141.14M121.49M118.43M66.64M70.99M83.89M336.48K51.82M33.65M
Long-Term Debt121.9M49.69M73.22M72.12M71.03M000000
Capital Lease Obligations41.67M11.46M7.52M12.95M17.33M20.36M19.67M21.5M7.1K34.3K5.46K
Deferred Tax Liabilities0000186K196K213.72K195.05K-201.26K-266.29K-588.49K
Other Non-Current Liabilities1.13M1.4M2.82M2.4M2.44M3.03M1.81M1.65M329.38K51.78M33.64M
Total Liabilities196.47M250.22M201.92M188.57M200.5M134.76M125.14M133.09M15.84M73.22M39.69M
Total Debt133.85M88.69M84.8M89.26M92.25M23.73M22.25M23.18M34.3K1.51M11.47K
Net Debt-50.8M22.75M-18.86M-40.3M-23.27M-113.97M-187.27M-204.05M-68.05M-7.04M-17.47M
Debt / Equity0.62x-1.25x0.65x0.78x0.13x0.09x0.12x0.00x--
Debt / EBITDA0.70x----------
Net Debt / EBITDA-0.26x----------
Interest Coverage26.25x-8.36x-10.14x-5.34x-25.21x-275.25x-415.60x-1125.19x-2336.42x-739.21x-788.70x
Total Equity215.22M-5.79M67.83M138.18M117.74M185.4M238.56M190.8M81.06M-47.37M-17.14M
Equity Growth %7436.4%-108.54%-50.91%17.36%-36.5%-22.28%25.03%135.39%271.14%-176.36%-
Book Value per Share2.22-0.070.972.452.614.206.325.754.28-5.53-0.89
Total Shareholders' Equity215.08M-5.79M67.83M138.18M117.74M185.4M238.56M190.8M81.06M-47.37M-17.14M
Common Stock3K3K3K2K2K2K1.72K1.43K1.06K342342
Retained Earnings-753.03M-816.22M-702.02M-554.23M-470.2M-340.59M-261.03M-203.04M-148.29M-65.42M-34.38M
Treasury Stock-18.19M0000000000
Accumulated OCI3.23M2.41M-3.72M-1.44M6.05M-2.67M-4.9M-1.79M293.67K-2.02M-661.11K
Minority Interest140K0000000000

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Thin cash cushion against burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Balance Sheet Swinging Between Recapitalization Cycles

Based on reported figures, MGTX's equity swung from $215.6M in 2026Q2 to negative $58.1M in 2026Q1, a reversal that appears driven by deferred revenue recognition and accumulated deficit rather than sustained operating strength. Total liabilities jumped to $302.8M in the same quarter.

The sharp equity contraction between 2026Q2 and 2026Q1 suggests that the balance sheet is highly sensitive to the timing of partner payments and milestone accounting. Retained earnings remain deeply negative at roughly -$753.0M, indicating that cumulative losses continue to erode the capital base. Investors should monitor whether the 2026Q3 rebound in equity proves durable or simply reflects another lumpy recognition event.

Debt Rising Faster Than Cash Generation

According to reported quarterly figures, total debt climbed from $80.5M in 2025Q2 to $133.9M in 2026Q3, while the debt-to-equity ratio fell to 0.62 only because equity was rebuilt, not because leverage was reduced in absolute terms.

Debt has increased by roughly two-thirds over the observed period, which may indicate growing reliance on borrowed capital to fund clinical operations. The apparent improvement in D/E is largely an artifact of equity recovery from a negative base, so it should not be read as deleveraging. Refinancing terms and maturity profile are not disclosed in the supplied data, warranting further investigation.

Cash Cushion Thin Relative to Operating Burn

Based on EDBL's reported figures, cash fell to $14.8M in 2025Q3 before recovering to $184.7M in 2026Q3, a volatile path that leaves the company's runway dependent on episodic inflows rather than a stable reserve.

The current ratio moved from 0.22 to 4.62 over the period, a swing that reflects the timing of current liabilities and deferred revenue more than structural liquidity improvement. With quarterly operating losses frequently in the range of $40M to $50M, the 2026Q3 cash balance may represent only a few quarters of burn. Investors should treat the recent cash build as contingent on partner timing rather than assured operating capacity.

Fixed Asset Base Anchors an Asset-Light Story

As reported in financial statements, net PP&E held relatively steady between $129.9M and $144.5M across the period, forming the dominant non-current asset while goodwill has nearly vanished to $17.0K in 2026Q3.

The stable PP&E base reflects the vertically integrated manufacturing footprint, which suggests the business is more asset-heavy than typical gene therapy peers. Goodwill erosion from $969.0K to $17.0K indicates minimal acquisition-related intangible risk, which is a positive for balance sheet quality. The key question is whether this fixed base can be productively utilized once clinical programs move toward commercial scale.

Deferred Revenue Signals Milestone Dependence

According to recent SEC filings, deferred revenue rose from $57.3M in 2024Q2 to $66.9M in 2025Q4 before collapsing to $16.8M in 2026Q3, suggesting partner-recognized obligations are being worked down rather than replenished.

The sharp decline in deferred revenue from roughly $67M to $16.8M implies that a large portion of previously collected partner funding has been recognized into income. This pattern may indicate that near-term revenue visibility is limited unless new collaboration milestones are secured. Investors should monitor future deferred revenue balances as a leading indicator of whether recognized income will persist.

Equity Rebound May Reflect Accounting Timing

Based on reported figures, the swing from negative equity of -$58.1M to positive $215.1M within two quarters appears more consistent with a single large recognition event than with a fundamental improvement in capital structure.

Headline equity recovery could mislead analysts into assuming the balance sheet has been repaired, when accumulated deficit of roughly -$753.0M remains the dominant force. The rebound coincides with a drop in deferred revenue, suggesting obligations were converted into recognized income rather than new capital being raised. Investors should avoid extrapolating the 2026Q3 equity level as a stable baseline.

MGTX — Frequently Asked Questions

Quick answers to the most common questions about buying MGTX stock.

What are the total assets of MeiraGTx Holdings plc (MGTX)?

As of 2025, MeiraGTx Holdings plc (MGTX) had total assets of $244.4M including $91.8M in current assets.

How much debt does MeiraGTx Holdings plc (MGTX) have?

MeiraGTx Holdings plc (MGTX) carries total debt of $88.7M, offset by $65.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of MeiraGTx Holdings plc?

MeiraGTx Holdings plc (MGTX) has total shareholders' equity (book value) of $-5.8M ($-0.07 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is MeiraGTx Holdings plc's current ratio and liquidity?

MeiraGTx Holdings plc (MGTX) reported a current ratio of 0.75x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.